A multi-center, Phase 3 study of lonafarnib (LNF) + ritonavir (RTV) and a combination arm of LNF + RTV + pegylated interferon-alfa (PEG IFN-α) in HDV-infected patients
Phase of Trial: Phase III
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Lonafarnib (Primary) ; Peginterferon alfa (Primary) ; Ritonavir (Primary)
- Indications Hepatitis D
- Focus Registrational; Therapeutic Use
- Acronyms D-LIVR
- Sponsors Eiger BioPharmaceuticals, Inc.
- 21 Mar 2018 According to Eiger BioPharmaceuticals media release, the company is currently defining primary and secondary endpoints with the FDA and plans to initiate the trial in 2H 2018.
- 09 Mar 2018 New trial record
- 06 Mar 2018 According to Eiger BioPharmaceuticals media release, the Company plans to initiate this trial by the end of the year 2018.